
News|Articles|May 1, 2002
Outcomes in ACS: GP IIb/IIIa inhibitor plus LMWH superior to GPs plus unfractionated heparin
Atlanta-The low-molecular-weight heparin enoxaparin improves outcomes compared with currently recommended therapy in patients with non-ST-segment elevation acute coronary syndromes (ACS) who are being treated with a glycoprotein (GP) IIb/IIIa inhibitor, said Shaun Goodman, MD.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicaid Unwinding Drops Coverage for Millions but Uninsured Rate Remains Steady
2
FDA Accepts NDA for Investigational Maintenance Asthma Treatment
3
Sponsored: The Teva Biosimilars Trend Report
4
Expert Discussion on Safety Results of Guselkumab for Crohn’s Disease
5